Jason A. Okazaki
Known title: Chief Operating OfficerCIK: 0001807214
Associated companies
Transaction History
| ASMB | ▲ Buy | Grant | 50,750 | $0 | 3/29/2026 | View on chart |
| ASMB | ▲ Buy | Grant | 94,250 | $0 | 3/29/2026 | View on chart |
| ASMB | ▼ Sell | Open Market | 355 | $3K | 3/31/2025 | View on chart |
| ASMB | ▼ Sell | Open Market | 197 | $3K | 10/3/2024 | View on chart |
| ASMB | ▼ Sell | Open Market | 981 | $14K | 8/2/2024 | View on chart |
| ASMB | ▼ Sell | Open Market | 549 | $8K | 5/23/2024 | View on chart |
| ASMB | ▼ Sell | Open Market | 1,569 | $20K | 4/30/2024 | View on chart |
| ASMB | ▲ Buy | Grant | 4,166 | $0 | 4/29/2024 | View on chart |
| ASMB | ▼ Sell | Open Market | 354 | $5K | 4/1/2024 | View on chart |
| ASMB | ▼ Sell | Open Market | 392 | $5K | 3/27/2024 | View on chart |
| ASMB | ▼ Sell | Open Market | 2,363 | $2K | 10/3/2023 | View on chart |
| ASMB | ▲ Buy | Grant | 12,500 | $0 | 10/2/2023 | View on chart |
| ASMB | ▼ Sell | Open Market | 11,827 | $13K | 8/2/2023 | View on chart |
| ASMB | ▲ Buy | Grant | 50,000 | $0 | 6/22/2023 | View on chart |
| ASMB | ▼ Sell | Open Market | 6,561 | $7K | 5/23/2023 | View on chart |
| ASMB | ▲ Buy | Grant | 35,000 | $0 | 5/22/2023 | View on chart |
| ASMB | ▼ Sell | Open Market | 4,247 | $3K | 3/30/2023 | View on chart |
| ASMB | ▼ Sell | Open Market | 4,693 | $5K | 3/27/2023 | View on chart |
| ASMB | ▲ Buy | Grant | 12,500 | $0 | 2/16/2023 | View on chart |
| ASMB | ▼ Sell | Open Market | 1,269 | $3K | 3/30/2022 | View on chart |
| ASMB | ▲ Buy | Grant | 31,250 | $0 | 3/29/2022 | View on chart |
| ASMB | ▼ Sell | Open Market | 4,617 | $10K | 3/28/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Assembly Biosciences to Present Phase 1a ABI-6250 Data at AASLD 2026
Assembly Biosciences announced that it will share Phase 1a safety, tolerability and target engagement results for its liver‑focused candidate ABI‑6250 at the AASLD Liver Meeting 2026. The data will be the first clinical readout for the program and could provide insight into the drug’s early performance. The announcement comes as the stock trades near its recent support level.
Assembly Biosciences to Present Phase 1a ABI-6250 Data at AASLD 2026. Assembly Biosciences announced that it will share Phase 1a safety, tolerability and target engagement results for its liver‑focused candidate ABI‑6250 at the AASLD Liver Meeting 2026. The data will be the first clinical readout for the program and could provide insight into the drug’s early performance. The announcement comes as the stock trades near its recent support level.